New cell therapy takes on advanced kidney cancer
NCT ID NCT04696731
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This early-stage study tests a new treatment called ALLO-316 for people with advanced or spreading clear cell kidney cancer who have already tried standard therapies like checkpoint inhibitors and VEGF inhibitors. The treatment uses specially designed immune cells from a donor to attack the cancer, given after a short chemotherapy course to prepare the body. The main goals are to find the safest dose and see if it helps control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
UCSF Medical Center
San Francisco, California, 94143, United States
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.